The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial
Safety Profile Toxicology studies using doses far exceeding human therapeutic ranges have not identified significant adverse effects
Less frequent AEs like hypoglycemia, is mostly seen in combination with insulin or sulfonylureas (157) and some reports of pancreatobiliary complications are partially explained by direct altered absorption of bile acids, rapid weight loss or changes in the gallbladder motility with increased risk of pancreatitis, even though it is extremely rare (160)
Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes
But there are clear exceptions
Bai M, Liang G, Sun R, Dong Y, Geng C, Wang B